State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
Bioorg Med Chem Lett. 2012 May 1;22(9):3181-7. doi: 10.1016/j.bmcl.2012.03.046. Epub 2012 Mar 16.
Acetylcholinesterase (AChE) is considered to be one of the most important targets for the treatment of Alzheimer's disease (AD). Previously our group has reported a series of tacrine-based hybrids as potent AChE inhibitors (AChEI). To discover more novel scaffolds, molecular docking and dynamics stimulation were applied to acquire the binding models of AChE with the most prominent compounds from our work. A structure-based pharmacophore model plus shape constraints was generated from the binding models and it was then employed to virtually screen commercial databases, giving a focused hit list of candidates. Subsequently, we scored the hit compounds by their molecular binding energies, which were calculated by MM/PBSA method. Fifteen compounds were selected and purchased for testing their anti-AChE effects, while seven of them showed inhibitory effects with IC(50) values ranging from 1.5 to 9.8 μM. The drug-like properties of these compounds, including LogD, AlogP, molecular volume and Lipinski rule of five, were also calculated. Compounds 12 and 16 (IC(50)=2.5 and 1.5 μM, respectively) exhibited potent activity and acceptable drug-like properties, thus might serve as leads for further modification. The data suggest that the presented model might be a valid approach for identification and development of new AChEIs.
乙酰胆碱酯酶(AChE)被认为是治疗阿尔茨海默病(AD)的最重要的靶标之一。 此前,我们的小组已经报道了一系列具有强效乙酰胆碱酯酶抑制剂(AChEI)活性的他克林类杂合化合物。 为了发现更多新的骨架,应用分子对接和动力学模拟来获得我们工作中最突出的化合物与 AChE 的结合模型。 从结合模型生成了基于结构的药效团模型加形状约束,并将其用于虚拟筛选商业数据库,得到了候选物的重点命中列表。 随后,我们根据 MM / PBSA 方法计算的分子结合能对命中化合物进行评分。 选择了十五种化合物进行抗 AChE 作用的测试,其中七种具有 1.5 至 9.8 μM 的 IC50 值的抑制作用。 还计算了这些化合物的类药性,包括 LogD、AlogP、分子体积和 Lipinski 五规则。 化合物 12 和 16(IC50分别为 2.5 和 1.5 μM)表现出很强的活性和可接受的类药性,因此可能成为进一步修饰的先导化合物。 数据表明,所提出的模型可能是鉴定和开发新型 AChEI 的有效方法。